Mumps disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MMP001 MIFTS: 61	Mumps Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps ¹² ⁷² ⁴⁹ ⁵¹ ⁴⁰ ³ ⁴¹ ¹⁴ ⁶⁹

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Certain infectious and parasitic diseases

Other viral diseases

Mumps

Mumps with other complications

Mumps without complication

External Ids:

Disease Ontology ¹² DOID:10264

ICD10 ³² B26 B26.9 B26.8

ICD9CM ³⁴ 072

MeSH ⁴¹ D009107

NCIt ⁴⁶ C29888

SNOMED-CT ⁶⁴ 154352008 186651001 186652008 more

UMLS ⁶⁹ C0026780

Sources

Summaries for Mumps

MedlinePlus : ⁴⁰ Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and rubella, and has symptoms including fever, headache and muscle aches. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include salivary gl, salivary gland and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : ¹² A viral infectious disease that results_in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted_by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted_by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : ³ Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Wikipedia : ⁷² Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Sources

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)

#	Related Disease	Score	Top Affiliating Genes
1	primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection	33.7	IFNAR2 STAT2
2	rubella	31.9	CD40LG HLA-DRB1 IFNAR2 IL10RB
3	measles	30.6	CD40LG CD46 IFNAR2 IFNG IL2 STAT1
4	recurrent respiratory papillomatosis	29.5	HLA-DRB1 IL2
5	panencephalitis, subacute sclerosing	29.4	CD40LG CD46
6	tetanus	29.0	CD40LG IFNG IL2 IL2RA
7	exanthem	29.0	CD40LG IL2 TNFRSF1A
8	rheumatic disease	28.8	CD40LG HLA-DRB1 IFNG IL2RA
9	posterior uveitis	28.7	IFNG IL2 IL2RA
10	combined immunodeficiency, x-linked	28.6	CD40LG IL2 IL2RA
11	bone inflammation disease	28.5	CD40LG HLA-DRB1 IFNG IL2
12	multiple sclerosis	27.8	HLA-DRB1 IFNG IL2 IL2RA STAT1 TNFRSF1A
13	congenital mumps	12.0
14	acute disseminated encephalomyelitis	11.3
15	endotheliitis	11.2
16	testicular microlithiasis	10.8
17	infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations	10.8
18	immunodeficiency 45	10.8
19	male infertility	10.8
20	salivary gland disease	10.8
21	immune-mediated encephalomyelitis	10.8
22	postinfectious encephalomyelitis	10.8
23	zika fever	10.4	CD40LG STAT1
24	axillary adenitis	10.4	CD40LG STAT1
25	orchitis	10.4
26	meningitis	10.3
27	chronic beryllium disease	10.3	HLA-DRB1 IFNG
28	campylobacteriosis	10.3	IFNG STAT1
29	coccidioidomycosis	10.3	CD40LG STAT1
30	aseptic meningitis	10.3
31	parotitis	10.2
32	rheumatoid factor-negative juvenile idiopathic arthritis	10.2	HLA-DRB1 IL2RA
33	aging	10.2
34	histoplasmosis	10.2	HLA-DRB1 IFNG STAT1
35	eosinophilia-myalgia syndrome	10.2	HLA-DRB1 IFNG
36	african tick-bite fever	10.2	CD40LG IFNG
37	rabies	10.2	CD40LG STAT1 STAT2
38	cat-scratch disease	10.2	CD40LG IFNG
39	hyperlucent lung	10.2	IFNG IL2RA
40	sporotrichosis	10.2	CD40LG IFNG
41	retinitis pigmentosa 75	10.2	IL10RB TNFRSF1A
42	opportunistic mycosis	10.1	CD40LG IFNG STAT1
43	severe acute respiratory syndrome	10.1	CD40LG IFNG STAT1
44	hepatitis	10.1
45	meningoencephalitis	10.1
46	influenza	10.1
47	encephalitis	10.1
48	central nervous system vasculitis	10.1	CD40LG HLA-DRB1 IFNG
49	hemorrhagic fever	10.1	CD40LG HLA-DRB1 IFNG
50	chronic graft versus host disease	10.1	IFNG IL2RA

Graphical network of the top 20 diseases related to Mumps:

Sources

Symptoms & Phenotypes for Mumps

Symptoms:

¹²

• fever
• headache
• muscle aches

• tiredness
• loss of appetite
• swollen

UMLS symptoms related to Mumps:

pruritus, fever

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.7	CD40LG IL2 IL2RA RIPK1 STAT1 TNFRSF1A
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.7	CD40LG IL2 IL2RA RIPK1 STAT1 TNFRSF1A

MGI Mouse Phenotypes related to Mumps:

⁴³

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.18	STAT1 STAT2 TNFRSF1A RIPK1 IRF2 IL12RB2
2	immune system	MP:0005387	10.07	RIPK1 STAT1 STAT2 TNFRSF1A IRF2 IL12RB2
3	cardiovascular system	MP:0005385	10.06	STAT1 TNFRSF1A IRAK1 CD40LG IL12RB2 CD46
4	endocrine/exocrine gland	MP:0005379	10.06	RIPK1 STAT1 TNFRSF1A IL12RB2 CD40LG IL2
5	digestive/alimentary	MP:0005381	10.03	RIPK1 STAT1 TNFRSF1A IL12RB2 IL2 IFNG
6	homeostasis/metabolism	MP:0005376	10.02	RIPK1 STAT1 TNFRSF1A IL10RB CD40LG IL12RB2
7	mortality/aging	MP:0010768	9.73	RIPK1 STAT1 STAT2 TNFRSF1A IRF2 CD40LG
8	liver/biliary system	MP:0005370	9.7	RIPK1 STAT1 TNFRSF1A IL10RB IL12RB2 IL2
9	neoplasm	MP:0002006	9.1	STAT1 TNFRSF1A IL12RB2 IFNAR2 IL2 IFNG

Sources

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vaccines

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Antibodies

Phase 4,Phase 2,Phase 1

Immunoglobulins

Phase 4,Phase 2,Phase 1

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4,Phase 3,Phase 2

Liver Extracts

Phase 4

Aluminum hydroxide

Approved, Investigational

Phase 3,Phase 2

21645-51-2

Tetracycline

Approved, Vet_approved

Phase 3,Phase 2

60-54-8

5353990

Lactitol

Investigational

Phase 3,Phase 2

585-86-4

3871

PENTA

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2

Anti-Infective Agents

Phase 3,Phase 2

Altretamine

Approved

Phase 2

645-05-6

2123

Daclizumab

Approved, Investigational

Phase 2

152923-56-3

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

6741

Mycophenolate mofetil

Approved, Investigational

Phase 2

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 2

24280-93-1

446541

Obinutuzumab

Approved, Investigational

Phase 2,Phase 1

949142-50-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

5755

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Anticoagulants

Phase 2

Fibrinolytic Agents

Phase 2

Antibodies, Monoclonal

Phase 2

Immunosuppressive Agents

Phase 2

Interleukin-2

Phase 2

Peripheral Nervous System Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Antiemetics

Phase 2

Anti-Inflammatory Agents

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Antitubercular Agents

Phase 2

Autonomic Agents

Phase 2

Gastrointestinal Agents

Phase 2

glucocorticoids

Phase 2

Hormone Antagonists

Phase 2

Hormones

Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2

Methylprednisolone acetate

Phase 2

Methylprednisolone Hemisuccinate

Phase 2

Neuroprotective Agents

Phase 2

Prednisolone acetate

Phase 2

Prednisolone hemisuccinate

Phase 2

Prednisolone phosphate

Phase 2

Protective Agents

Phase 2

gamma-Globulins

Phase 1

Immunoglobulins, Intravenous

Phase 1

Rho(D) Immune Globulin

Phase 1

Acetylcholine

Approved

51-84-3

187

Adalimumab

Approved

331731-18-1

16219006

Azathioprine

Approved

446-86-6

2265

Interventional clinical trials:

(show top 50) (show all 137)

#	Name	Status	NCT ID	Phase	Drugs
1	The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine	Unknown status	NCT02153866	Phase 4
2	Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations	Completed	NCT01777529	Phase 4
3	Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine	Completed	NCT02880865	Phase 4
4	Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis	Completed	NCT00731965	Phase 4
5	Measles, Mumps, and Rubella (MMR) Immunity in College Students	Completed	NCT00962819	Phase 4
6	Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00126997	Phase 4
7	Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine	Completed	NCT00313950	Phase 4
8	Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine	Completed	NCT03160820	Phase 4
9	MMR Vaccination Among HIV-infected Adults	Completed	NCT02724852	Phase 4
10	Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)	Completed	NCT00326183	Phase 4
11	Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)	Completed	NCT00312858	Phase 4
12	Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.	Completed	NCT00388440	Phase 4
13	MMR and Varicella Vaccine in Premature Infants	Completed	NCT00156559	Phase 4
14	Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children	Completed	NCT02253407	Phase 4
15	Safety Study of a Refrigerator-stable Formulation of VARIVAX®	Completed	NCT00432731	Phase 4
16	Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV	Completed	NCT00329251	Phase 4
17	Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts	Recruiting	NCT03183765	Phase 4	Measles-Mumps-Rubella Vaccine
18	Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines	Recruiting	NCT03368495	Phase 4
19	Homeopathic Vaccine Trial	Recruiting	NCT02825368	Phase 4
20	Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients	Recruiting	NCT01770119	Phase 4
21	Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR	Active, not recruiting	NCT02325310	Phase 4
22	Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination	Not yet recruiting	NCT03350698	Phase 4
23	Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines	Terminated	NCT00138255	Phase 4
24	Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants	Unknown status	NCT01763268	Phase 2, Phase 3
25	Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants	Completed	NCT02692599	Phase 3
26	Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older	Completed	NCT02058563	Phase 3
27	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)	Completed	NCT00092391	Phase 3
28	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00127023	Phase 3
29	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00127010	Phase 3
30	Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers	Completed	NCT01188343	Phase 3
31	Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)	Completed	NCT01536405	Phase 3
32	Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.	Completed	NCT01991899	Phase 3
33	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life	Completed	NCT01681992	Phase 3
34	Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age	Completed	NCT02184572	Phase 3
35	Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)	Completed	NCT00092430	Phase 3
36	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age	Completed	NCT01621802	Phase 3
37	Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136	Completed	NCT00751348	Phase 3
38	Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children	Completed	NCT00192491	Phase 3
39	Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children	Completed	NCT00197015	Phase 3
40	Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox	Completed	NCT00226499	Phase 3
41	Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children	Completed	NCT01506193	Phase 3
42	ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)	Completed	NCT00975507	Phase 3
43	Safety Study of ProQuad® rHA in Infants (V221-037)	Completed	NCT00560755	Phase 3
44	Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM	Completed	NCT00969436	Phase 3
45	Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly	Completed	NCT00432042	Phase 3
46	Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine	Completed	NCT00406211	Phase 3
47	Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age	Completed	NCT01702428	Phase 3
48	Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)	Completed	NCT00985153	Phase 3
49	A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)	Completed	NCT00985166	Phase 3
50	Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers	Completed	NCT00422292	Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Sources

Genetic Tests for Mumps

Sources

Anatomical Context for Mumps

The Foundational Model of Anatomy Ontology organs/tissues related to Mumps:

¹⁸

Salivary Gl

MalaCards organs/tissues related to Mumps:

³⁸

Salivary Gland, Testes, Liver, B Cells, Skin, Heart, T Cells

Sources

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 839)

#	Title	Authors	Year
1	Granulomatosis With Polyangiitis Associated With Mumps Viral Infection. ( 29424761 )	Droz N....Kontzias A.	2018
2	Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )	Keskin Yildirim Z....Buyukavci M.	2018
3	Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )	Seagle E.E....McLean H.Q.	2018
4	Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China. ( 29377772 )	Ma C....Hao L.	2018
5	Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )	Voigt E.A....Poland G.A.	2018
6	Mumps infection but not childhood vaccination induces persistent polyfunctional CD8<sup>+</sup>T-cell memory. ( 29339261 )	de Wit J....Kaaijk P.	2018
7	Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. ( 29324728 )	Marin M....Patel M.	2018
8	Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )	Bavdekar A....Kulkarni P.S.	2018
9	Utility of neutralization test for the laboratory diagnosis of suspected mumps cases. ( 29363797 )	Vaidya S.R....Walimbe A.M.	2018
10	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )	Pandit A....Issa N.C.	2018
11	A Complication after Percutaneous Nephrolithotomy: Anesthesia Mumps. ( 28928593 )	ErkiliAs E....Aksoy M.	2017
12	Tackling mumps in a public health setting: loopholes in disease surveillance. ( 28843408 )	Gopakumar K.G.	2017
13	Shift within age-groups of mumps incidence, hospitalizations and severe complications in a highly vaccinated population. Spain, 1998-2014. ( 28687402 )	LA^pez-Perea N....MartA-nez de AragA^n M.V.	2017
14	Magnetic Resonance Imaging Findings of Mumps Meningoencephalitis with Bilateral Hippocampal Lesions without Preceding Acute Parotitis: A Case Report. ( 28246518 )	Woo A.R....Baek J.H.	2017
15	Mumps Virus SH Protein Inhibits NF-I_B Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes. ( 28659487 )	Franz S....Friedrich N.	2017
16	Three Complete Genome Sequences of Genotype G Mumps Virus from the 2016 Outbreak in Arkansas, USA. ( 28798162 )	Alkam D....Ussery D.	2017
17	Anti-mumps IgM antibody positive rate with sudden sensorineural hearing loss using second-generation enzyme immunoassay: A retrospective, multi-institutional investigation in Hokkaido, Japan. ( 29224848 )	Fukuda A....Homma A.	2017
18	Mumps Epidemiology and Mumps Virus Genotypes Circulating in Mainland China during 2013-2015. ( 28085897 )	Cui A....Xu W.	2017
19	Reemergence of mumps in SALo Paulo, Brazil - the urgent need for booster shot campaign to prevent a serious infectious disease. ( 28954076 )	Urbano P.R....Romano C.M.	2017
20	Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )	Meacham R.K....Thompson J.W.	2017
21	Heat shock protein 90 ensures efficient mumps virus replication by assisting with viral polymerase complex formation. ( 28053100 )	Katoh H....Takeda M.	2017
22	Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. ( 28558983 )	Perez-Vilar S....Zuber P.L.F.	2017
23	Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )	Willame C....Praet N.	2017
24	The potential dysfunction of otolith organs in patients after mumps infection. ( 28746415 )	Zhou Y.J....Chi F.L.	2017
25	Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Evidence-based Medicine viewpoint. ( 29317561 )	Mathew J.L.	2017
26	A questionnaire survey for parents in Nara prefecture, Japan about mumps vaccination. ( 29288550 )	Kitano T....Yoshida S.	2017
27	Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )	Tielemans S.M.A.J....Knol M.J.	2017
28	Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Pediatrician's Viewpoint. ( 29317562 )	Vashishtha V.M.	2017
29	The pathogenesis of iodide mumps: A case report. ( 29382013 )	Zhang G....Liu J.	2017
30	Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )	Latner D.R....Hickman C.J.	2017
31	Severe Complications of Mumps. ( 28891485 )	Rajma J....Arun A.C.	2017
32	Pseudotumoral acute cerebellitis associated with mumps infection in a child. ( 28868306 )	Ajmi H....Abroug S.	2017
33	A case of mumps-related acute encephalopathy with biphasic seizures and late reduced diffusion. ( 28501474 )	Hazama K....Watanabe M.	2017
34	Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital. ( 28775976 )	Kitano T....Yoshida S.	2017
35	Mumps makes a comeback: What nurses need to know. ( 28027128 )	Barbel P....Heavey E.	2017
36	An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. ( 28903791 )	Willocks L.J....Pollock K.G.J.	2017
37	Complete Genome Sequence of Mumps Virus Isolated from Karnataka State, India. ( 28082488 )	Vaidya S.R....Hamde V.S.	2017
38	Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart. ( 28709617 )	Morales-Raya C....Postigo-Llorente C.	2017
39	Mumps transmission in social networks: a cohort study. ( 28068914 )	HahnAc S....de Melker H.	2017
40	Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. ( 28806450 )	Macartney K....Wood N.	2017
41	Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )	Kreidl P....de Kat C.	2017
42	Ongoing mumps outbreak in Israel, January to August 2017. ( 28877843 )	Indenbaum V....Singer S.R.	2017
43	Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States. ( 28818890 )	MagaA+a L.C....Rota P.A.	2017
44	Third Dose of MMR Vaccine for Mumps Control. ( 29239596 )	Webber B.J....Costello A.A.	2017
45	Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit. ( 29261361 )	Pettinicchio V....Franco E.	2017
46	Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )	Verma A....Srivastava A.	2017
47	Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Virologist's viewpoint. ( 29317563 )	Ramachandran V.G.	2017
48	Modelling the Transmission Dynamics and Control of Mumps in Mainland China. ( 29278378 )	Li Y....Wang L.	2017
49	A New CombinedA VaccineA Against Measles, Mumps, Rubella and Varicella in India. ( 29317560 )	Shah N....Kolhapure S.	2017
50	Forecasting the Incidence of Mumps in Zibo City Based on a SARIMA Model. ( 28817101 )	Xu Q....Li X.	2017

Sources

Genes for Mumps

Genes related to Mumps (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication	PubmedIds
1	STAT2	Signal Transducer And Activator Of Transcription 2	Protein Coding	36.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications Drugs & Compounds (show sections)	16051811
2	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	32.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications Drugs & Compounds (show sections)	12917439 16051811
3	IFNAR2	Interferon Alpha And Beta Receptor Subunit 2	Protein Coding	26.78	GeneCards inferred via : Disorders Publications (show sections)
4	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	26.1	GeneCards inferred via : Publications Proteins (show sections)
5	IRAK1	Interleukin 1 Receptor Associated Kinase 1	Protein Coding	25.8	GeneCards inferred via : Publications Proteins (show sections)
6	RIPK1	Receptor Interacting Serine/Threonine Kinase 1	Protein Coding	25.8	GeneCards inferred via : Publications Proteins (show sections)
7	CD40LG	CD40 Ligand	Protein Coding	24.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CD46	CD46 Molecule	Protein Coding	21.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	IL12RB2	Interleukin 12 Receptor Subunit Beta 2	Protein Coding	21.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	IRF2	Interferon Regulatory Factor 2	Protein Coding	21.39	Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	8981353
11	IL10RB	Interleukin 10 Receptor Subunit Beta	Protein Coding	21.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	IL2	Interleukin 2	Protein Coding	21.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	IFNG	Interferon Gamma	Protein Coding	21.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	21.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	21.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mumps

Sources

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Sources

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 60)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶² Show member pathways Immune System ⁶² Neutrophil degranulation ⁶²	13.9	CD40LG CD46 HLA-DRB1 IFNAR2 IFNG IL10RB
2	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.83	CD40LG IL10RB IL12RB2 IL2 IL2RA IRAK1
3	PEDF Induced Signaling ⁶⁰ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁰ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶⁰ Glucocorticoid Receptor Signaling ⁶⁰ IL-6 Pathway ⁶⁰ MIF Mediated Glucocorticoid Regulation ⁶⁰ MIF Regulation of Innate Immune Cells ⁶⁰ NFAT Signaling and Lymphocyte Interactions ⁶⁰ PGC1Alpha Pathway ⁶⁰ RAR-Gamma-RXR-Alpha Degradation ⁶⁰ STAT3 Pathway ⁶⁰	13.64	CD40LG IFNAR2 IFNG IL10RB IL12RB2 IL2
4	TGF-Beta Pathway ⁶⁰ Show member pathways JAK-STAT Pathway ⁶⁰ JNK Pathway ⁶⁰ MAPK Family Pathway ⁶⁰ Regulation of eIF4 and p70S6K ⁶⁰ SOCS Pathway ⁶⁰	13.54	IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
5	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.4	CD40LG IL10RB IL12RB2 IL2 IL2RA IRAK1
6	PAK Pathway ⁶⁰ Show member pathways Antioxidant Action of Vitamin-C ⁶⁰ Epithelial Adherens Junctions ⁶⁰	13.27	CD40LG IL10RB IL12RB2 IL2 IL2RA TNFRSF1A
7	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	13.24	HLA-DRB1 IFNG IL2 IL2RA IRAK1 STAT1
8	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.99	IFNAR2 IL2 IL2RA STAT1 STAT2 TNFRSF1A
9	Toll-Like receptor Signaling Pathways ⁶¹ Show member pathways IL-1 Family Signaling Pathways ⁶¹ Immune response IL-1 signaling pathway ²¹ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²¹ Inflammasome Activation Pathways ⁶¹ Mucin expression in CF via TLRs, EGFR signaling pathways ²¹ NOD-like receptor signaling pathway ³⁶ NOD-like Receptor Signaling Pathways ⁶¹ Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶¹	12.94	IFNAR2 IRAK1 RIPK1 STAT1 STAT2
10	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶⁰ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶⁰ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.89	CD40LG HLA-DRB1 IFNG IL2 IL2RA STAT1
11	Pathways in cancer ³⁶	12.89	IFNAR2 IFNG IL12RB2 IL2 IL2RA STAT1
12	Cytokine Signaling in Immune system ⁶² Show member pathways Signaling by Interleukins ⁶²	12.88	CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
13	NF-KappaB Family Pathway ⁶⁰ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁰	12.71	CD40LG IL2 IRAK1 RIPK1 TNFRSF1A
14	4-1BB Pathway ⁶⁰ Show member pathways CD27 Pathway ⁶⁰ CD40 Signaling ⁶⁰ CMV and MAPK Pathways ⁶⁰ NF-KappaB Activation by EBV ⁶⁰ NF-kappaB Activation by Viruses ⁶⁰ PKR Pathway ⁶⁰ SUMO Pathway ⁶⁰ TNFR2 Pathway ⁶⁰	12.69	CD40LG IFNG RIPK1 STAT1 TNFRSF1A
15	Influenza A ³⁶ Show member pathways Herpes simplex infection ³⁶ Measles ³⁶	12.65	CD46 HLA-DRB1 IFNAR2 IFNG IL2 IL2RA
16	Immune response IL-23 signaling pathway ²¹ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁰ Development Angiopoietin - Tie2 signaling ²¹ Development PDGF signaling via STATs and NF-kB ²¹ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²¹ Rac1/Pak1/p38/MMP-2 pathway ¹	12.62	IFNG IL10RB IL2 RIPK1 STAT1
17	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶⁰ Immune response IL-22 signaling pathway ²¹ Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.62	HLA-DRB1 IFNG IL10RB IL12RB2 IL2 IL2RA
18	Immune response NFAT in immune response ²¹ Show member pathways Immune response CD28 signaling ²¹ Immune response ICOS pathway in T-helper cell ²¹ Immune response T cell receptor signaling pathway ²¹	12.61	CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
19	Interferon gamma signaling ⁶² Show member pathways Interferon Signaling ⁶² Regulation of IFNG signaling ⁶²	12.6	HLA-DRB1 IFNAR2 IFNG IRF2 STAT1 STAT2
20	Kaposi's sarcoma-associated herpesvirus infection ³⁶ Show member pathways Hepatitis B ³⁶	12.54	IFNAR2 STAT1 STAT2 TNFRSF1A
21	Toll-like receptor signaling pathway ¹ ³⁶ Show member pathways Chagas disease (American trypanosomiasis) ³⁶	12.54	IFNAR2 IFNG IL2 IRAK1 RIPK1 STAT1
22	HTLV-I infection ³⁶	12.42	HLA-DRB1 IL2 IL2RA TNFRSF1A
23	ICos-ICosL Pathway in T-Helper Cell ⁶⁰ Show member pathways Calcium Mediated T-Cell Apoptosis ⁶⁰ CD28 Signaling in T-Helper Cell ⁶⁰	12.39	CD40LG HLA-DRB1 IL2 IL2RA
24	Epstein-Barr virus infection ³⁶	12.36	HLA-DRB1 IFNG IL10RB IRAK1 RIPK1
25	Type I Interferon Signaling Pathways ⁶¹ Show member pathways Inhibition of TSC complex formation by PKB ⁶² Interferon Pathway ⁶⁰ Type II Interferon Signaling Pathways ⁶¹	12.31	IFNAR2 IFNG STAT1 STAT2
26	Jak-STAT signaling pathway (KEGG) ³⁶ Show member pathways B-Cell Development ⁶⁰ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶¹ Interleukin-19, 20, 22, 24 ⁶² Jak/STAT Signaling Pathway ⁶¹	12.3	IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
27	Tuberculosis ³⁶	12.28	HLA-DRB1 IFNG IL10RB IRAK1 STAT1 TNFRSF1A
28	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.27	CD40LG HLA-DRB1 IFNG IL10RB IRAK1 STAT1
29	Necroptosis ³⁶ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.24	IFNAR2 IFNG RIPK1 STAT1 STAT2 TNFRSF1A
30	Immune response IFN alpha/beta signaling pathway ²¹ Show member pathways Cytokine Network ⁶⁰ Interferon alpha/beta signaling ⁶² Regulation of IFNA signaling ⁶²	12.18	IFNAR2 IFNG IL2 IRF2 STAT1 STAT2
31	Hepatitis C ³⁶	12.13	IFNAR2 RIPK1 STAT1 STAT2 TNFRSF1A
32	Osteoclast differentiation ³⁶	12.12	IFNAR2 IFNG STAT1 STAT2 TNFRSF1A
33	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	12.11	IFNG IL2 IL2RA STAT1
34	MAPK Pathway ⁶⁸ Show member pathways Toll-like Receptor Pathway ⁶⁸	12	IL2 IL2RA STAT1
35	IL27-mediated signaling events ¹ Show member pathways IL-12 Family Signaling Pathways ⁶¹ Interleukin-12 signaling ⁶² Th1 Differentiation Pathway ⁶¹	12	IFNG IL12RB2 IL2 STAT1 STAT2
36	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶¹	11.97	IFNG IL2 IL2RA
37	IL12-mediated signaling events ¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²¹	11.97	HLA-DRB1 IFNG IL12RB2 IL2 IL2RA IRAK1
38	NF-kappa B signaling pathway ³⁶	11.95	CD40LG IRAK1 RIPK1 TNFRSF1A
39	NF-kappaB Signaling ⁴	11.88	CD40LG CD46 IFNG IL2 IL2RA IRAK1
40	Innate Lymphoid Cell Differentiation Pathways ⁶¹	11.87	IFNG IL12RB2 IL2 IL2RA
41	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ¹	11.84	CD40LG IFNG IL2 IL2RA
42	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway ²¹ Show member pathways Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway ²¹	11.82	CD40LG IRAK1 RIPK1 TNFRSF1A
43	Glucocorticoid receptor regulatory network ¹	11.81	IFNG IL2 STAT1
44	CXCR4-mediated signaling events ¹	11.77	HLA-DRB1 STAT1 STAT2
45	Dendritic Cells Developmental Lineage Pathway ⁶¹	11.76	IFNG IL2 IRF2
46	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²¹	11.74	CD40LG IFNG IL2 TNFRSF1A
47	Downstream signaling in naive CD8+ T cells ¹ Show member pathways Ras signaling in the CD4+ TCR pathway ¹	11.72	IFNAR2 IFNG IL2 IL2RA
48	Regulation of Telomerase ¹	11.7	IFNAR2 IFNG IL2
49	Jak-Stat Signaling Pathway (sino) ⁶³	11.67	IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
50	Interferon type I signaling pathways ¹	11.62	IFNAR2 STAT1 STAT2

Sources

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface	GO:0009986	9.55	CD40LG CD46 HLA-DRB1 IL2RA TNFRSF1A
2	plasma membrane	GO:0005886	9.36	CD40LG CD46 HLA-DRB1 IFNAR2 IL10RB IL12RB2
3	external side of plasma membrane	GO:0009897	9.26	CD40LG HLA-DRB1 IL12RB2 IL2RA

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune system process	GO:0002376	9.97	CD46 HLA-DRB1 IL2 IL2RA IRAK1
2	inflammatory response	GO:0006954	9.93	CD40LG IL10RB IL2RA TNFRSF1A
3	cytokine-mediated signaling pathway	GO:0019221	9.83	IL10RB IL12RB2 IRAK1 TNFRSF1A
4	cell surface receptor signaling pathway	GO:0007166	9.83	IFNAR2 IFNG IL12RB2 IL2RA TNFRSF1A
5	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.81	CD40LG IRAK1 RIPK1
6	tumor necrosis factor-mediated signaling pathway	GO:0033209	9.8	CD40LG RIPK1 STAT1 TNFRSF1A
7	immune response	GO:0006955	9.8	CD40LG HLA-DRB1 IFNG IL10RB IL2 IL2RA
8	negative regulation of inflammatory response	GO:0050728	9.77	IL2 IL2RA TNFRSF1A
9	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.73	IFNG IL2 TNFRSF1A
10	interleukin-12-mediated signaling pathway	GO:0035722	9.71	IFNG IL12RB2 STAT1
11	viral process	GO:0016032	9.7	CD46 HLA-DRB1 IRAK1 RIPK1 STAT1 STAT2
12	interferon-gamma-mediated signaling pathway	GO:0060333	9.67	HLA-DRB1 IFNG IRF2 STAT1
13	JAK-STAT cascade	GO:0007259	9.65	IFNAR2 STAT1 STAT2
14	regulation of type I interferon-mediated signaling pathway	GO:0060338	9.63	IFNAR2 STAT1 STAT2
15	positive regulation of T cell differentiation	GO:0045582	9.62	IL2 IL2RA
16	positive regulation of T cell proliferation	GO:0042102	9.62	CD40LG CD46 IL2 IL2RA
17	regulation of interferon-gamma-mediated signaling pathway	GO:0060334	9.61	IFNG STAT1
18	inflammatory response to antigenic stimulus	GO:0002437	9.61	HLA-DRB1 IL2RA
19	positive regulation of regulatory T cell differentiation	GO:0045591	9.59	CD46 IL2
20	response to interferon-beta	GO:0035456	9.58	IFNAR2 STAT1
21	death-inducing signaling complex assembly	GO:0071550	9.58	RIPK1 TNFRSF1A
22	regulation of regulatory T cell differentiation	GO:0045589	9.58	IFNG IL2 IL2RA
23	negative regulation of lymphocyte proliferation	GO:0050672	9.55	IL2 IL2RA
24	regulation of T cell homeostatic proliferation	GO:0046013	9.51	IL2 IL2RA
25	defense response to virus	GO:0051607	9.43	IFNAR2 IFNG IL10RB IRF2 STAT1 STAT2
26	type I interferon signaling pathway	GO:0060337	9.02	IFNAR2 IRAK1 IRF2 STAT1 STAT2
27	apoptotic process	GO:0006915	10.02	IFNG IL2RA RIPK1 STAT1 TNFRSF1A

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ubiquitin-like protein ligase binding	GO:0044389	8.62	STAT1 STAT2

Sources

Sources for Mumps

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia